Clauser P, et al. - In this prospective, randomized, intraindividual comparative study, researchers compared a three-quarter (0.075 mmol/kg) dose of the high-relaxivity gadolinium-based contrast agent (GBCA) gadobenate dimeglumine, with a 1.5-fold higher than on-label dose (0.15 mmol/kg) of gadoterate meglumine for breast lesion detection and characterization at 3T CE-MRI. Patients with imaging abnormalities (BI-RADS 0, 4, 5) were eligible for conventional imaging. For breast lesion detection, a 0.075 mmol/kg dose of the high-relaxivity contrast agent gadobenate was not inferior to a 0.15 mmol/kg dose of gadoterate. Findings revealed that gadobenate allowed increased specificity and precision. For diagnostically challenging indications like locoregional staging and problem-solving cases, the use of a reduced dose of gadobenate would appear especially beneficial.